Investing.com — Here is your Pro Recap of 5 head-turning deal dispatches you may have missed last week: Chevron to buy Hess for $53 billion, Vista Equity Partners to pick up EngageSmart, Roche to buy Telavant Holdings from Roivant and) for $53 billion, or $171 per share, based on Chevron's Oct. 20 closing price. As per the terms of the deal, each Hess shareholder will get 1.0250 Chevron shares for their Hess share, bringing the combined enterprise's value to $60B, including debt.
This report surfaced shortly after SK Hynix said it opposes a merger between Kioxia and Western Digital, arguing that it undervalues its Kioxia investment's value. Omni, for its part, said it has"fully complied with all the required provisions of the Agreement and Plan of Merger" and said the merger is"legally binding" and intends to enforce it.
This acquisition gives Roche exclusive rights over RVT-3101's development, production, and marketing in the US and Japan. The antibody, set for Phase 3 trials, is primarily aimed at treating inflammatory bowel disease and potentially other related ailments.
ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว
Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้
แหล่ง: MarketWatch - 🏆 3. / 97 อ่านเพิ่มเติม »